original ) (raw )Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
Masaru Oba
Oncology letters, 2011
View PDFchevron_right
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
Masahiro Takeuchi , Toshikazu Moriwaki
European Journal of Cancer, 2014
View PDFchevron_right
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice
Manabu Muto
Gastric Cancer
View PDFchevron_right
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
David Cella
Anti-Cancer Drugs, 2011
View PDFchevron_right
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Atsuo Takashima
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016
View PDFchevron_right
Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer
Junichi Sakamoto
Gastric Cancer, 2019
View PDFchevron_right
Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study
Young Do
Journal of Korean medical science, 2005
View PDFchevron_right
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Masaru Oba
Oncology letters, 2011
View PDFchevron_right
Single-Agent Irinotecan as Second-Line Treatment for Advanced Gastric Cancer
Mutlu Demiray
Tumori Journal, 2003
View PDFchevron_right
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
keon park
BMC Cancer, 2010
View PDFchevron_right
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer
Yuksel Kucukzeybek
Asian Pacific journal of cancer prevention : APJCP, 2012
View PDFchevron_right
Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy
Jong Chun
View PDFchevron_right
A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer
Dong Shin
Cancer research and treatment : official journal of Korean Cancer Association, 2006
View PDFchevron_right
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer
Toshikazu Moriwaki
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014
View PDFchevron_right
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes
Dong Gyu Shin
Anti Cancer Drugs, 2005
View PDFchevron_right
A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II)
Junichi Sakamoto
European journal of cancer (Oxford, England : 1990), 2018
View PDFchevron_right
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Yoshito Komatsu
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014
View PDFchevron_right
Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer
Junichi Sakamoto
European journal of cancer (Oxford, England : 1990), 2016
View PDFchevron_right
A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer who relapsed after S-1 adjuvant therapy, XP after TS-1 adjuvant failure (XParTS)
Junichi Sakamoto
Journal of Clinical Oncology, 2015
View PDFchevron_right
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO
Yasemin Doğan
European Journal of Cancer, 2011
View PDFchevron_right
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer
Mitsuru Sasako
Gastric Cancer, 2013
View PDFchevron_right
Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study
Hiroshi Mihara
Gastroenterology research and practice, 2012
View PDFchevron_right
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer
Kenji Shimada
Cancer Chemotherapy and Pharmacology, 2001
View PDFchevron_right
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
Vahur Valvere
Annals of Oncology, 2004
View PDFchevron_right
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
E. Goker
Annals of Oncology, 2008
View PDFchevron_right
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002)
Mitsuru Sasako
Clinical Oncology, 2016
View PDFchevron_right
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin
Ken Shimada
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016
View PDFchevron_right
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
Deepti Singh
Cancer, 2007
View PDFchevron_right
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
Atsuo Takashima
Journal of Cancer Research and Clinical Oncology, 2010
View PDFchevron_right
Efficacy and Feasibility of Combination Chemotherapy with S-1 and Cisplatin (2 Weeks Regimen) for Advanced Gastric Cancer
Takahiro Kogawa
Japanese Journal of Clinical Oncology, 2010
View PDFchevron_right